Research article

**Anti-tumor effect of Liqi, a traditional Chinese medicine prescription, in tumor bearing mice**

Deng-Bo Ji\(^1\), Jia Ye\(^*\)\(^1\), Yi-Min Jiang\(^2\) and Bo-Wen Qian\(^3\)

Address: \(^1\)Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, PR China, \(^2\)Medical and Healthy Analysis Center, Peking University, Beijing, 100191, PR China and \(^3\)Department of Traditional Chinese Medicine, Shanghai University of Chinese Traditional Medicine, Shanghai, 201203, PR China

Email: Deng-Bo Ji - jidengbo@bjmu.edu.cn; Jia Ye\(^*\) - yejia@bjmu.edu.cn; Yi-Min Jiang - jiangyimin@bjmu.edu.cn; Bo-Wen Qian - qianbowen@gmail.com

\(^*\) Corresponding author

**Abstract**

**Background:** Liqi, an herbal preparation used in traditional Chinese medicine, has been used to treat cancer in China for centuries. We investigated the anti-tumor effects of liqi and their mechanisms in mice that had been xenografted with tumors.

**Methods:** Sarcoma 180 tumor, Lewis lung carcinoma, and SGC-7901 cells were implanted in BALB/c mice, C57BL/6 mice, and BALB/c nude mice, respectively. Liqi was administered to subgroups of these mice. The tumor weight and size were measured. Cell cycle analysis and T lymphocyte subsets were determined by flow cytometry. The activity of NK cells and TNF was tested using cytotoxicity assay on YAC-1 cells and L929 cells, respectively, and the activity of IL-2 was tested with an IL-2-dependent CTLL-2 cell proliferation assay. Platelet aggregation was monitored by measuring electric impedance, and the levels of thromboxane A\(_2\) (TXA\(_2\)) and prostacyclin (PGI\(_2\)) in blood were measured by \(125^I\)-TXB\(_2\) and \(125^I\)-Keto-PGF\(_{1\alpha}\) radioimmunoassay.

**Results:** The results showed that liqi inhibited tumor growth in tumor-implanted mice and arrested the cell proliferation in the G0/G1 phase and reduced the portion of cells in S and G2/M phase for SGC-7901 cells. Liqi increased the activity of NK cells and TNF-\(\alpha\), stimulated IL-2 production and activity, and regulated T lymphocyte subpopulations. Liqi inhibited the Lewis lung carcinoma metastasis by inhibiting platelet aggregation and normalizing the balance between TXA\(_2\) and PGI\(_2\).

**Conclusion:** All these findings demonstrated that liqi has an anti-tumor effect in vivo. The mechanism may be related to immune regulation and anticoagulation effects.

---

**Background**

Cancer is a leading cause of death worldwide. The main curative therapies for cancer are surgery and radiation, although these are most successful if the tumor is diagnosed at an early stage. For advanced tumors, chemotherapy is the treatment of choice, and although these drugs are effective, they are associated with severe adverse events and drug resistance [1], and new therapeutic options are needed. In the search for new cancer therapeutics with low toxicity and few side effects, traditional Chinese medicines are promising candidates.
Liqi prescription, a traditional Chinese medicine made from *Poncirus trifoliate* (L.) Raf, *Akebia Trifoliate Koidz*, *Citrus medica var. sarcodactylis Swingle* and *Saussurea lappa*, has been used to treat malignancies in traditional Chinese medicine for centuries. The main active constituents are coumarins, flavonoids, and terpenoids in *Poncirus trifoliate* (L.) Raf; triterpene and triterpenoid saponin in *Akebia Trifoliate Koidz*; terpenoids and polysaccharide in *Citrus medica var. sarcodactylis Swingle*; and sesquiterpenes and sesquiterpene lactones in *Saussurea lappa* [2-5]. Recent studies have demonstrated their multiple pharmacologic actions, including anti-inflammatory, anti-allergic and antibacterial effects; promoting gastrointestinal motor function; and inhibiting cancer cell growth in vitro. *Poncirus trifoliate* inhibits human colon cancer HT-29 cell growth and induces human leukemia HL-60 cell apoptosis [6,7]. *Akebia Trifoliate Koidz* inhibits the growth of breast cancer cell lines MDA-MB-231 and BT-483 [8]. *Saussurea lappa* induces G2-growth arrest and apoptosis in AGS gastric cancer cells [9].

However, little research has been conducted on the anti-tumor effects of liqi in vivo. In the present experiment, we studied the anti-tumor effect of liqi and explored the mechanism of any effect on tumor-bearing mice.

**Methods**

**Materials**

*Poncirus trifoliate* (L.) Raf, *Akebia Trifoliate Koidz*, *Citrus medica var. sarcodactylis Swingle* and *Saussurea lappa* were purchased from Shanghai Pharmaceutical Co., Shanghai, China, and were authenticated by Prof. Bo-Wen Qian, Department of Traditional Chinese Medicine, Shanghai University of Chinese Traditional Medicine, Shanghai, China. We also used the following materials: Concanavalin A (ConA), lipopolysaccharide (LPS), propidium iodide, ADP (Sigma, St Louis, MO); [3H]TdR (China Institute of Atomic Energy, Beijing, China); human recombinant interleukin-2 (rIL-2) (Boehringer Mannheim GmbH, Germany); human recombinant tumor necrosis factor (TNF) (Collaborative Biomedical Products, Bedford, MA); FITC-conjugated antibodies to CD3, CD4, CD8 (Pharmediate, Becton Dickinson, Franklin Lakes, NJ); lactic dehydrogenase (LDH) Cytotox assay kit (Promega, Madison, WI); 125I-TXB, and 125I-Keto-PGF1α radioimmunoassays (RIA kits, Suzhou Medical College, Suzhou, China); RPMI Medium 1640 (Invitrogen, Carlsbad, CA); fetal bovine serum (FBS, HyClone Corporation, Logan, UT).

**Cell culture**

Mouse sarcoma 180 tumor cells, Lewis lung carcinoma cells, and human gastric carcinoma cell line SGC-7901 were donated by Shanghai Institute of Materia Medica, Chinese Academy of Sciences (Shanghai, China). YAC-1, CTLL-2, and L929 cells were provided by School of Medicine, Shanghai Jiao Tong University (Shanghai, China), and were grown routinely in RPMI-1640 supplemented with 10% heat-inactivated fetal bovine serum (FBS). The medium was supplemented with 100 U/mL penicillin and 100 U/mL streptomycin; 10 ng/mL rhIL-2 was added in the culture medium of CTLL-2 cells, and the cells were incubated in a humidified atmosphere, with 5% CO2 in air at 37°C.

**Animals**

Male BALB/c mice and C57BL/6 mice (6 to 8 weeks old) were provided by the Department of Shanghai Institute of Planned Parenthood Research, Fudan University, Shanghai, China. The animals were group-housed in a regulated environment (22 ± 1°C, relative humidity 60 ± 5%) with a 12-h light and 12-h dark cycle (08:00–20:00, light). Food and water were given *ad libitum*. Food pellets meet Feed Standard of Medical Laboratory Animal of China. Food composition is as follows: protein 18–25%, fat 4–5%, calcium 1.0–1.8%, phosphonium 0.6–1.2%, vitamins A 12500–15000 IU/kg, vitamins D 1250–1500 IU/kg, fiber 4–5% and moisture 8–10%, lysine 0.98–1.42%, cystine 0.76–1.10%, tryptophane 0.22–0.34%.

BALB/c strain athymic nu/nu mice were provided by Shanghai Cancer Institute, China. Female mice (6 to 8 weeks old) were used in this study. The animals were maintained in a specific pathogen free animal care facility, under controlled conditions (25 ± 2°C, 50%–60% relative humidity and 12-hour light cycle). They were fed with autoclaved tap water and food *ad libitum*. The laboratory animal protocol used for this study was approved by the committee for control and supervision of experimental animals of Shanghai University of Chinese Traditional Medicine.

**Preparation of Liqi**

Liqi was prepared as a lyophilized powder of hot water extracts from 4 species of medical herbs: *Citrus medica var. sarcodactylis Swingle, Akebia Trifoliate Koidz, Poncirus trifoliate (L.) Raf* and *Saussurea lappa*. Briefly, the above materials were mixed in a ratio of 3:2:1:7:1.7 and decocted three times with boiling distilled water for 1 h. The decoction was filtered, collected, concentrated, and lyophilized. The yield of liqi was approximately 20%. Liqi was dissolved in distilled water and administered in a volume of 10 ml/kg. In this experiment, the animal dose of liqi was dose of crude drug.

**Tumor models and in vivo treatment regimen**

Sarcoma 180 tumor cells were subcutaneously implanted (2 × 106 S180 tumor cells suspended in 50 μl of Ca2+- and Mg2+-free phosphate-buffered saline [PBS]) in the right axillary region of syngeneic BALB/c mice. Lewis lung carcinoma cells were subcutaneously implanted (2 × 106 LLC tumor cells suspended in 50 μl of PBS) in the right axillary
region of syngeneic C57BL/6 mice. SGC-7901 cells were subcutaneously implanted (2×10^5 cells suspended in 0.2 ml of PBS) in the right axillary region of BALB/c nude mice. After 24 h, they were weighed and randomized into 5 groups (12 mice each): a normal control group, a group that was injected with tumor cells but treated with water only, and three groups that were injected with tumor cells and treated with different doses of liqi (12.5, 25 and 50 g/kg). Treatments were administrated at about 9 o’clock daily by gavage, and mice were weighted daily.

**Anti-tumor activity**

On day 21, all mice were weighed and euthanized, and tumors were removed and weighed. The tumor repress rate was calculated as follows: The repression rate (%) = (mean weight of tumors of water-treated mice – mean weight of tumors of liqi-treated mice)/mean weight of tumors of water-treated mice × 100% [10].

**Cell cycle analysis of SGC-7901 cells from xenografted mice**

For cell cycle analysis, cells were harvested from xenografted BALB/c nude mice. On day 21, tumor tissues were immediately removed and disaggregated in PBS and filtered through a double layer of stainless-steel mesh using a syringe plunger to obtain single cell suspension. Cell cycle distribution was evaluated by propidium iodide staining of nuclei and flow cytometric analysis [11]. Briefly, pelleted cells were washed twice with PBS and then fixed in 70% cold ethanol overnight at -20°C. After washing again, the cells were resuspended in PBS containing RNase A (200 μg/mL) and incubated at 37°C for 30 min. Propidium iodide was added to the cell suspensions at a final concentration of 100 μg/mL. The fluorescence intensity of PI was analyzed with a FACS calibur flow cytometer (FACS Calibur; Becton Dickinson, USA) and Cell Quest software.

**Flow cytometry for peripheral blood T lymphocyte subsets**

On day 12, the heparinized peripheral blood was collected from the orbital plexuses of the tumor-bearing C57BL/6 mice to analyze peripheral blood lymphocyte subsets by flow cytometry. Samples were prepared by adding 5 μl of fluorescent monoclonal antibodies against CD3, CD4, and CD8 to 100 μl of heparinized whole blood. CD3+CD4+ (T helper cells) and CD3+CD8+ (T suppressor cells) were counted. Lymphocytes were separated from erythrocytes lysed. The tubes were placed on ice in the dark until flow cytometric analysis; five thousand cells were collected for each sample, and data were analyzed by using flow cytometry.

**IL-2 activity assay**

In order to determine the effects of Liqi on IL-2 production and activity, splenic lymphocytes from tumor bearing BALB/c mice were prepared after treatment with liqi (50 g/kg) for 12 days as described above. Spleens of mice were removed under sterile conditions and disaggregated in PBS and filtered through a double layer of stainless-steel mesh using a syringe plunger to obtain single cell suspension. Lymphocytes were collected and suspended in RPMI-1640 medium at a concentration of 1×10^7 cells/mL, with ConA added to a final concentration of 5 μg/mL. After incubating at 37°C and 5% CO2 for 24 hours, cells supernatants containing extracellular IL-2 were collected and stored at -20°C until assay.

IL-2 activity was tested using an IL-2-dependent CTLL-2 cell proliferation assay [12]. The CTLL-2 cells were washed in medium containing 2% FBS and incubated for 2 h without IL-2. The cells were then cultured (1× 10^5 cells/mL) in 96-well plates with 0.6 ng/mL of rhIL-2 or with spleen cell supernatant for 24 h. Six hours before the end, 0.5 μCi [3H]TdR 50 μl was added to each well. The [3H]TdR incorporation was measured with a liquid-scintillator (Beckman Co, USA) counting technique. The results were described as the average of triplicate Bq (specific radioactivity of [3H]TdR was 20 μCi/mmol).

**Evaluation of NK cell cytotoxicity**

NK cells from tumor bearing BALB/c mice spleens were prepared as described above and used as effector cells. YAC-1 cells, mouse lymphoma sensitive to NK cells were used as target cells. Effector and target cells resuspended in RPMI-1640 medium were added to each well of a 96-well round-bottom microculture plate in triplicate to obtain an effector/target (E/T) ratio of 100:1 and incubated for 16 h. The amount of released lactate dehydrogenase (LDH) in culture supernatants was determined using the LDH Cytotox assay kit according to the manufacturer’s instructions. The OD was read at 490 nm with a Microplate Reader. The percentage of NK cell cytotoxicity was calculated with the formula: cytotoxicity (%) = (experimental release – effector spontaneous release – target spontaneous release)/ (target maximum release – target spontaneous release) × 100. Experimental release stood for LDH that was released from cocultures at an E/T ratio of 100:1, effector spontaneous release or target spontaneous release was spontaneous LDH release from effector or target cells incubated with medium alone, and target maximum release was obtained from target cells lysed with the lysis solution [13].

**Production and activity assay of TNF**

On day 12, tumor-bearing BALB/c mice received 20 μg/0.2 ml of LPS intravenously. After 1.5 h, blood samples were collected from the orbital plexuses of the mice. The sera were stored at -20°C until used for the TNF assay. TNF activity was determined by a cytotoxicity assay on L929 cells [14]. Briefly, L929 cells were plated at the density of 3.5 × 10^4/ml in 96-well plates and incubated at 37°C in a 5% CO2 atmosphere for 24 h. Samples or
recombinant TNF (as the standard) were incubated for a further 24 h, in the presence of 2 μg/ml actinomycin D. Cell survival was determined by measuring optical density at 630 nm after crystal violet staining. The diluted samples were assayed in triplicate. The percentage of cell destruction at a particular dilution was calculated as \((A_{\text{cont}} - A_{\text{dil}}/A_{\text{cont}}) \times 100\), where \(A_{\text{cont}}\) is absorbance in control wells and \(A_{\text{dil}}\) is absorbance in wells of a particular dilution of sample. The percent cytotoxicities were plotted against the logarithm of sample quantity. One unit of TNF activity was defined as the sample quantity required to achieve 50% cytotoxicity in the reaction.

### Inhibition of Metastasis in Mice

The tumor-bearing C57BL/6 mice were sacrificed on the 21st day. Lungs were removed and fixed in 4% formalin. Tumor colonies were counted under microscope (× 200).

### Platelet Aggregation Assay

Platelet aggregation was monitored by measuring electric impedance [15] using a whole-blood aggregometer (model OX-200; Shanghai Medical University Instrument Factory, Shanghai, China). On day 21, heparinized blood was drawn from tumor-bearing C57BL mice by cardiac puncture. Whole blood was then diluted with an equal amount of normal saline. The sample was placed in a plastic cuvette containing a magnetic stir bar and was kept at 37 °C for 5 minutes before analysis. The platelet aggregation was then initiated by adding 10 μl 2 μmol/L ADP and monitored for up to 5 minutes.

### Measurement of TXA₂ and PGI₂

On day 21, blood samples were collected from the femoral artery of the tumor-bearing C57BL/6 mice and transferred into a plastic tube prefilled with EDTA-Na₂ (9:1). The tube was centrifuged at 1200 × g at 4 °C for 10 min. The supernatant was frozen at -20 °C under physiologic conditions. The TXA₂ with a half-life of approximately 30 sec under physiologic conditions was measured using its stable metabolite TXB₂, and PGI₂ using its stable metabolite 6-keto-prostaglandin F1α [16]. All determinations were performed using commercially available 125I-TXB₂ and 125I-Keto-PGF1α radioimmunoassays (RIA kits, Suzhou Medical College, Suzhou, China).

### Statistical analysis

The data are expressed as mean ± S.D. Student’s t-test or Dunnet t-test was used to compare the differences between treated groups and control groups, and differences were considered significant at \(P < 0.05\).

### Results

#### Effect of liqi on tumor growth in the tumor-transplanted mice

To explore the role of liqi on tumor growth in mouse Sarcoma 180 transplanted into BALB/c mice and Lewis lung carcinoma transplanted into C57BL/6 mice, we treated tumor-bearing mice with various doses of liqi (12.5, 25, 50 g/kg). For Sarcoma 180-bearing BALB/c mice, liqi significantly decreased the tumor growth, with 29.69% inhibition at 25 g/kg and 34.54% inhibition at 50 g/kg \((p < 0.05, \text{Table 1})\). For Lewis lung carcinoma-bearing C57BL/6 mice, liqi significantly decreased the tumor growth, with 35.20% inhibition at 25 g/kg and 42.54% inhibition at 50 g/kg \((p < 0.05, \text{Table 2})\). There was no significant difference between the body weight of the liqi-treated group and that of the normal group.

To determine whether liqi could suppress human gastric carcinoma growth in vivo, we implanted SGC-7901 in nude mice. As shown in Figure 1, Liqi (50 g/kg) reduced the tumor weight significantly compared with the model group \((p < 0.05)\), with inhibition 27.42%.

#### Effect of Liqi on SGC-7901 cells cycle from xenografted mice

As shown in Table 3, cell cycle analysis showed accumulation of SGC-7901 cells in the G0/G1 phase \((p < 0.01)\) and decreased cell numbers in the S \((p < 0.01)\) and G2/M phases in mice treated with 50 g/kg of liqi.

#### Effect of liqi on T lymphocyte subpopulations in tumor-bearing mice

As shown in Figure 2, the numbers of CD3+ CD4+ T cells and the CD4+/CD8+ ratios in peripheral blood were consistently lower in the tumor-bearing mice than in the normal mice \((P < 0.05)\). Among tumor-bearing mice, those treated with liqi had consistently higher percentages of

### Table 1: Effect of Liqi on mouse Sarcoma 180 transplanted into BALB/c mice

| Groups | Doses (g/kg) | n  | Mean weight of tumor (g) | Inhibition (%) |
|--------|-------------|----|-------------------------|---------------|
| Normal | 0           | 12 | 0                       | 0             |
| Model  | 0           | 12 | 1.65 ± 0.47             | 0             |
| Liqi   | 12.5        | 12 | 1.28 ± 0.50             | 22.42%        |
|        | 25          | 12 | 1.16 ± 0.49*            | 29.69%        |
|        | 50          | 12 | 1.08 ± 0.50*            | 34.54%        |

Each group consists of 12 mice. Results are presented as mean ± S.D. *\(p < 0.05\), compared with model group.
CD3+CD4+ T lymphocytes than did untreated mice ($P < 0.05$). A similar difference was seen in the ratios of CD4+/CD8+; however, the percentages of CD3+CD8+ T lymphocytes were slightly lower in liqi-treated mice.

**Effect of liqi on IL-2 activity in tumor-bearing mice**

To illustrate whether liqi could affect the IL-2 production and activity in splenocytes, the murine T-cell line CTLL-2 was used. As shown in Figure 3, splenocytes supernatants from tumor-bearing mice inhibited the proliferation of CTLL-2 cells compared with the normal group ($P < 0.01$). After treatment with liqi (50 g/kg), splenocyte supernatants showed a greater proliferation of CTLL-2 cells than in splenocytes from untreated mice ($P < 0.01$).

**Effect of liqi on NK cell cytotoxicity in tumor-bearing mice**

The activation of NK cells is a good indicator of antitumor effect. After tumor-bearing mice were treated with liqi (50 g/kg), splenic lymphocytes showed more cytotoxicity than did splenocytes from untreated mice ($P < 0.05$) (Figure 4). These results indicate that liqi increased NK cell cytotoxicity.

**Effect of liqi on TNF-α activity in tumor-bearing mice**

We checked whether Liqi interfered in the LPS-induced TNF-α activity in tumor bearing mice. As shown in Figure 5, Liqi (50 g/kg) significantly increased TNF-α cytotoxicity on L929 cells ($P < 0.01$).

**Effect of liqi on metastasis of tumor cells to the lung**

As shown in Figure 6, liqi prevented metastases to the lung. Fewer tumor colonies were observed in the lungs of mice treated with liqi compared with untreated mice ($P < 0.05$). The inhibition effect was 33.89%.

**Effect of liqi on platelet aggregation in tumor-bearing mice**

As shown in Figure 7, increased platelet aggregation was observed in tumor-bearing mice compared with the normal group ($P < 0.05$); however, liqi (50 g/kg) significantly decreased platelet aggregation compared with untreated mice ($P < 0.05$).

**Effect of liqi on TXA2 and PGI2 in tumor-bearing mice**

As shown in Table 4, TXB2 concentration was increased and 6-Keto-PGF1α was decreased in the blood plasma of tumor-bearing mice compared with normal group ($P < 0.01$); consequently, the ratio of TXB2 to 6-Keto-PGF1α was significantly increased compared with that of the normal group ($P < 0.01$). However, when the tumor-bearing mice were treated with liqi (50 g/kg), the level of TXB2 was markedly lowered, 6-Keto-PGF1α was raised, and the ratio

| Groups | Doses (g/kg) | n  | Mean weight of tumor (g) | Inhibition (%) |
|--------|-------------|----|--------------------------|---------------|
| Normal | 0           | 12 | 0                        | 0             |
| Model  | 0           | 12 | 1.57 ± 0.62              | 29.06%        |
| Liqi   | 12.5        | 12 | 1.11 ± 0.51              | 35.20%        |
|        | 25          | 12 | 1.02 ± 0.48              | 42.54%        |
|        | 50          | 12 | 0.90 ± 0.44              |               |

Each group consists of 12 mice. Results are presented as mean ± S.D. *$P < 0.05$, compared with model group.

---

**Table 2: Effect of Liqi on mouse Lewis lung carcinoma transplanted into C57BL/6 mice.**

| Groups | Doses (g/kg) | n  | Mean weight of tumor (g) | Inhibition (%) |
|--------|-------------|----|--------------------------|---------------|
| Normal | 0           | 12 | 0                        | 0             |
| Model  | 0           | 12 | 1.57 ± 0.62              | 29.06%        |
| Liqi   | 12.5        | 12 | 1.11 ± 0.51              | 35.20%        |
|        | 25          | 12 | 1.02 ± 0.48              | 42.54%        |
|        | 50          | 12 | 0.90 ± 0.44              |               |

Each group consists of 12 mice. Results are presented as mean ± S.D. *$P < 0.05$, compared with model group.

---

**Table 3: Effect of Liqi on cell cycle of SGC-7901 cells from xenografted mice.**

| Groups | Dose (g/kg) | n  | Cell cycle (%) |
|--------|-------------|----|----------------|
|        |             |    | G1  | S       | G2+M   |
| Model  | 0           | 7  | 49.7 ± 6.8 | 44.9 ± 6.6 | 5.4 ± 0.76 |
| Liqi   | 50          | 7  | 61.8 ± 6.4** | 34.0 ± 5.3** | 4.13 ± 1.2** |

Each group consists of 7 mice. Results are presented as mean ± S.D. **$P < 0.01$, compared with model group.**

---

**Figure 1**

Effect of Liqi on SGC7901 transplanted into BALB/c nu/nu mice. SGC-7901 cells were subcutaneously implanted (2 x 10^5 cells suspended in 0.2 ml of PBS) in the right axillary region of BALB/c nude mice. After 24 h, Liqi (12.5, 25, 50 g/kg) was administrated daily by gavage for 21 days. The tumor weight was measured. Results are expressed as the mean ± S.D. of 12 mice. *$P < 0.05$, compared with untreated control of tumor-transplanted animals (model group).
of TXB₂ to 6-Keto-PGF₁α was significantly decreased compared with untreated mice (P < 0.01).

Discussion
Our findings suggest that liqi has a significant anti-tumor effect against Sarcoma 180 tumor and Lewis lung carcinoma, which is likely because of its immune-modulating effects. Liqi enhanced NK cell activity, increased the Th/Ts ratio, stimulated the production and activity of IL-2 in splenocytes, and increased TNF-α activity in serum. Moreover, liqi inhibited the Lewis lung carcinoma metastasis, which might be related to its inhibition of platelet aggregation and normalization of the balance between TXA₂ and PGI₂. Furthermore, liqi inhibited the human gastric carcinoma growth in xenografted mice. We demonstrated that liqi has an anti-tumor effect and this effect may be related to immune regulation and anticoagulation.

Previous reports have shown that the constituents of liqi had an anti-tumor effect in vitro. We have shown that treatment with liqi inhibited tumor growth in vivo. We found that liqi arrested the proliferation of the human gastric carcinoma cell line SGC-7901 from xenografted mice in the G0/G1 phase and reduced the proportion of cells in the S and G2/M phases (mitotic/dividing phases).

Although the mechanisms underlying liqi’s anti-tumor effect may be complex, our findings demonstrated that this effect was most likely related to immune regulation. Host immunity is implicated in the development and progression of malignant disease. Mice with tumors show a change in T lymphocyte subpopulations and NK cell activity. T cells can affect tumor cells directly or can act indirectly by producing cytokines that amplify cytotoxic T lymphocyte responses or activate NK cells and macrophages. Experimental studies have outlined the critical
role of CD4+ and CD8+ T cells and NK cells in mediating anti-tumor immunity [17-20]. The present study confirms the decrease in the ratio of CD4+/CD8+ with increasing tumor burden, which appeared to result mainly from a decrease in CD4+ T cells and an increase in CD8+ T cells. However, the results also showed that the number of CD4+ T cells and the CD4+/CD8+ ratio increased significantly after administration of liqi, while the number of CD8+ cells decreased. This finding indicates that liqi can regulate the disordering of T lymphocyte subsets and improve the immune response.

We also found that administering liqi increased the activity of NK cells in tumor-bearing mice. NK cells are the major mediators of the innate anti-tumor immune responses; they eradicate tumors by recognizing stress-inducible ligands on tumors and execute tumor cells with perforin and granzyme in vivo [21]. NK cells eradicate solid tumors by apoptosis [21]. Liqi augments the cytotoxic potential of NK cells in vivo. Our data show that liqi reversed tumor-mediated suppression of NK cell cytotoxicity.

We found that the anti-tumor activity of liqi might also be related to its regulatory effects on IL-2 and TNF-α, both of which play important roles in cancer therapy [22,23]. IL-2 has an anti-tumor effect because of its immune-regulating function [24]. TNF-α had an anti-tumor activity against sarcoma 180. In addition to direct cytotoxicity against tumor cells, TNF induced a host-mediated factor which contributed to the anti-tumor effects [25]. Rychly J et al. [26] also demonstrated that TNF-α induced strong necrosis in sarcoma 180 in vivo and showed total regression. The infiltration of inflammatory cells was observed in the sarcoma 180 tumor. Their result suggested that cell infiltration may be of importance for tumor regression. A synergistic anti-tumor effect has been observed when TNF-α is combined with IL-2 [27]. We demonstrate that liqi can stimulate the production and activity of IL-2 and TNF-α in mouse Sarcoma 180 tumor-bearing mice.

Furthermore, we demonstrated that liqi inhibited metastasis of Lewis lung carcinomas. Metastasis is the major cause of death from cancer. Tumor-induced platelet aggregation is believed to protect tumor cells from immunological assault in circulation [28]; platelets protect tumors from TNF-α-mediated cytotoxicity [29]. Platelets also facilitate the adhesion of tumor cells to the vascular endothelium and release a number of growth factors that...
promote tumor growth [30]. Recently, it has been reported that platelets contribute to tumor-induced angiogenesis by releasing angiogenic growth factors, such as vascular endothelial growth factor [31]. Our results demonstrated that platelet aggregation was increased in C57BL mice with Lewis lung carcinomas, and Liqi inhibited platelet aggregation in these mice.

PGI₂, a potent vasodilator and inhibitor of platelet aggregation, is an important antithrombotic mediator in vivo [32]. It also inhibits carcinogenesis [33]. Conversely, TXA₂ stimulates platelet aggregation and amplifies the response to other platelet agonists [34]. We demonstrated that the level of PGI₂ in serum was decreased and the level of TXA₂ was increased, which resulted in an increased T/P ratio in C₅₇BL mice with Lewis lung carcinomas. However, Liqi treatment inhibited the increase in the T/P ratio.

Conclusion
In summary, we demonstrated for the first time that liqi has a significant inhibitory effect on tumor growth in vivo. This inhibition may be related to the immunoregulatory effects of liqi, such as stimulating IL-2 and TNF-α production and activity and increasing the ratio of CD4+ to CD8+ T lymphocytes and the activity of NK cells. These data lead us to propose that the anticancer function of liqi is underpinned by the improvement of immune function. Furthermore, liqi has a significant inhibitory effect on tumor metastasis, which is most likely related to its anticoagulation effects. These findings provide an experimental basis for the use of liqi for tumor therapy. The findings

Table 4: Effect of Liqi on TXA₂ and PGI₂ in tumor-bearing mice.

| Groups   | Doses (g/kg) | TXB₂ (pg/ml)       | 6-Keto-PGF₁₀ (pg/ml) | T/P      |
|----------|--------------|--------------------|----------------------|---------|
| Normal   | 0            | 1011.64 ± 102.57***| 404.12 ± 51.33***    | 2.72 ± 0.78*** |
| Model    | 0            | 1583.5 ± 102.45    | 178 ± 31.12          | 8.76 ± 1.67    |
| Liqi     | 50           | 1858.43 ± 148.45***| 323.15 ± 104.25**    | 4.81 ± 1.22**  |

Each group consists of 12 mice. Results are presented as mean ± S.D. ***P < 0.01, compared with model group.
of our study may shed light on the pharmacologic basis for the clinical application of traditional Chinese medicine in treating cancer.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
DBJ carried out the studies, performed the statistical analysis and drafted the manuscript. JY carried out the study design, participated in the studies and drafted the manuscript. BWQ conceived of the study and participated in its design and coordination. YMJ participated in cell cycle and peripheral blood T lymphocyte subsets analysis. All authors read and approved the final manuscript.

Acknowledgements
The authors thank Professor Er Xin Yu, Yong Xiang Zhang and Yuan Fu Ji for their support.

References
1. Kellof G. Perspective on cancer chemoprevention research and drug development. Adv Cancer Res 2000; 78:199-334.
2. Xu GH, Kim JA, Kim SY, Ryu JCh, Kim YS, Jung SH, Kim MK, Lee SH: Terpenoids and Coumarins Isolated from the Fruits of Poncirus trifoliata. Chem Pharm Bull 2008, 56:839-842.
3. Mimaki Y, Kuroda M, Yokosuka A: Triterpenes and triterpene saponins from the stems of Akebia trifoliate. Chem Pharm Bull 2003, 51:960.
4. Gao Y, Huang H, Xu H, Diao Y, Dong Z: Studies on the chemical constituents of Citrus medica var. sarcodactylis. Zhong Yao Cai 2002, 25:639-640. (In Chinese).
5. Talwar KK, Singh IP, Kalsi PS: A sesquiterpenoid with plant growth regulatory activity from Saussurea lappa. Phytochemistry 1992, 31:336-338.
6. Jayaprakasha GK, Mandadi KK, Poulose SM, Jadegoud Y, Nagana Gowda GA, Paul BS: Inhibition of colon cancer cell growth and antioxidant activity of bioactive compounds from Poncirus trifoliata (L) Raf. Bioorg Med Chem 2007, 15:4923-4932.
7. Yi JM, Kim MS, Koo HN, Song BK, Yoo YH, Kim HM: Poncirus trifoliata fruit induces apoptosis in human promyelocytic leukemia cells. Clin Chim Acta 2004, 340:179-185.
8. Loo WT, Chen JP, Chow LW, Chou JW: Effects of Shugansanjie Tang on matrix metalloproteinases 1, 3 and 9 and telomerase reverse transcriptase expression in human breast cells in vitro. Biomed Pharmacother 2007, 61:601-605.
9. Ko SG, Kim HP, Jin DH, Bae HS, Kim SH, Park CH, Lee JW: Saussurea lappa induces G2-growth arrest and apoptosis in AGS gastric cancer cells. Cancer Lett 2005, 220:1-11.
10. Sun GP, Wang H, Xu SP, Shen YX, Wu Q, Chen ZhD, Wei W: Anti-tumor effects of paenolin in a Hepa-hepatoma bearing mouse model via induction of tumor cell apoptosis and stimulation of IL-2 and TNF-alpha production. Eur J Pharmacol 2008, 584:246-252.
11. Li C, Kumar S, Ponting J, Carette M, Allan E: Glucosaminylmuramyl dipeptide (GMDP) modulates endothelial cell activities in vitro but has no effects on angiogenesis in vivo. Infamm Res 1997, 46:348-353.
12. Zhang LL, Wei W, Yan SH, Hu XY, Sun WY: Therapeutic effects of glucosides of Cheonan olespeciosa on collagen-induced arthritis in mice. Acta Pharmacol Sin 2004, 25:1495-1501.
13. Sarangi K, Ghosh D, Bhutta SK, Mallick SK, Maiti TK: Anti-tumor and immunomodulating effects of Pleurotus ostreatus mycelia-derived proteoglycans. Int Immunopharmacol 2006, 6:1287-1297.
14. Wang YP, Li XY, Song ChQ, Hu ZB: Effect of astragaloside IV on T, B lymphocyte proliferation and peritoneal macrophage function in mice. Acta Pharmacol Sin 2002, 23:263-266.
15. Kunita A, Kashima TG, Morishita Y, Fukayama M, Kato Y, Tsuruo T, Fujita N: The Platelet Aggregation-Inducing Factor Aggrus/Podoplanin Promotes Pulmonary Metastasis. Am J Pathol 2007, 170:1337-1347.
16. Furushashi N, Tsuijei M, Kimura H, Yajima A, Nagae H, Kimura C: Maternal and fetal atri atrial natriuretic peptide levels, maternal plasma rennin activity, angiotensin II, prostacyclin and thromboxane A2 levels in normal and preeclamptic pregnancies. Tohoku J Exp Med 1991, 165:79-86.
17. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H: The central role of CD44+ T cells in the antitumor immune response. J Exp Med 1998, 188:2357-2368.
18. Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, Sato T, Habu S, Tashiro H, Sato M, Ohita A: Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999, 190:617-627.
19. van den Broek MF, Kagi D, Zinkernagel RM, Hengartner H: Perforin dependence of natural killer cell-mediated tumor control in vivo. Eur J Immunol 1995, 25(11):3514-3516.
20. Smyth MJ, Tha KY, Cerny AB, Kim JH, MB, Forbes CA, Scalzo AA. Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol 1999, 162:6658-6662.
21. Varalakshmi Ch, Ali AM, Pardhasaradhi BV, Srivastava RM, Singh S, Khar A: Immunomodulatory effects of curcumin: In-vivo. Int Immunopharmacol 2000, 1:707-714.
22. Tamada K, Chen L: Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules. Cancer Immunol Immunother 2006, 55:335-362.
23. Glick RP, Lichtor T, Lin H, Tarlock K, Cohen EP: Immunogen therapy as a treatment for malignant brain tumors in young mice. J Neurosurg 2006, 105:65-70.
24. Antony PA, Restifo NP: CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunology 2005, 28:120-128.
25. Arai H, Oida H, Yurugi-Kobayashi T, Yamashita JK, Katagiri H, Majima M, Yokode M, Kita T, Narumiya S: Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. Atherosclerosis 2002, 166:27-37.
26. Haranaka K, Satomi N, Sakurai A: Anti-tumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 1984, 34:263-267.
27. Rychly J, Knuppel E, Krygier-Sopala A, Nizze H, Kuchnio M, Krafft SK: DNA cytometric and histologic findings in mice tumors (BP and S180) with different response to treatment with tumor necrosis factor. Acta Oncol 1990, 29:47-51.
28. Su Y, Wu YM: The study of synergistic cytotoxicity of tumor necrosis factor alpha and interleukin-2 against lung adenocarcinoma cell. Chin J Cancer Res 2000, 19:779-781.
29. Honn KV, Tang DG, Crissman JD: Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev 1999, 11:325-351.
30. Philippe C, Philippe B, Fouqueray B, Perez J, Lebret P, Baud L: Protection from tumor necrosis factor-mediated cytolysis by platelets. Am J Pathol 1993, 143:1713-1723.
31. Mehta P: Potential role of platelets in the pathogenesis of tumor metastasis. Blood 1984, 63:55-63.
32. Verheul HM, Hoekman K, Lupu F, Broxterman HJ, Valk P van der, Karsen AK, Pinedo HM: Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res 2000, 6:166-171.
33. Kobayashi T, Tahara Y, Matsumoto M, Iuchi M, Sano H, Murayama T, Arai H, Oida H, Yurugi-Kobayashi T, Yamashita JK, Kazaghi H, Majima M, Yokode M, Kita T, Narumiya S: Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004, 114:784-794.
34. Keith RL, Miller YE, Hoshikawa Y, Moore MD, Gesell TL, Gao B, Malkin DM, Golpon HA, Gerson LW, Lawson JA, FitzGerald GA: Podoplanin Promotes Pulmonary Metastasis. Am J Pathol 2007, 170:1337-1347.
35. Fujikawa M, Kondo Y, Takeda A, Kawano T, Nishimura T, Tanaka Y, Arakawa H, Yamanaka T, Ohtani M, Yamane T: Murine Lung Cancer. Cancer Res 2002, 62:188:740.
36. Cheng Y, Austin SC, Rroca B, Koller BH, Coffman TM, Grosser T, Lawson JA, FitzGerald GA: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002, 296:539-541.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6882/9/20/prepub